BMS and Harvard to discover new fibrotic disease therapies

Immunomedics expands AZ clinical collaboration to include NSCLC
Credit: Shutterstock.com/ uwadol Jaturawutthichai

Bristol-Myers Squibb and the Harvard Fibrosis Network of the Harvard Stem Cell Institute are teaming up to discover and develop potential new therapies for fibrotic diseases.

The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.

Fibrotic diseases impact many organs or tissues in the body, and are characterized by injury and chronic inflammation that lead to excess collagen deposition and scar formation in the affected organ or tissue.

The scarring response compromises function and ultimately leads to organ failure. Treatments for fibrotic diseases are currently limited, and there is a significant unmet need for new options.

As per the agreement, leading academic investigators of hepatic and cardiac fibrosis from the Harvard Fibrosis Network will collaborate closely with leading scientists from Bristol-Myers Squibb on four projects over three years.

Specific research projects will focus on applied fibrosis biology, identification of non-invasive biomarkers, and novel targets for potential anti-fibrotic therapies, in the areas of hepatic and cardiac fibrosis.